Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 16385C104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Morgan Stanley
13G/A
Amendment 1
|
3.2% |
8/7/2025
Event 7/31/2025
|
|
| Morgan Stanley | 3.2% | ||
| Morgan Stanley & Co. LLC | 2.2% | ||
|
Morgan Stanley
13G
|
8.4% |
8/7/2025
Event 6/30/2025
|
|
| Morgan Stanley | 8.4% | ||
| Morgan Stanley & Co. LLC | 7.5% | ||
|
OrbiMed Israel BioFund GP Limited Partnership
13D/A
Amendment 5
|
4.8% |
6/23/2025
Event 6/18/2025
|
|
| Orbimed Israel Biofund GP Limited Partnership | 4.8% | ||
| Orbimed Israel GP Ltd. | 4.8% | ||
| Chimovits Erez | 4.8% | ||
| Gordon Carl L | 4.8% | ||
|
Sphera Funds Management Ltd.
13G/A
Amendment 1
|
4.8% |
4/10/2025
Event 3/31/2025
|
|
| Sphera Funds Management Ltd. | 4.8% | ||
| Sphera Global Healthcare GP Ltd. | 4.8% | ||
| Sphera Global Healthcare Management LP. | 4.8% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q2 | 15 | 4.23 M | $4.91 M |
| 2025 Q1 | 18 | 3.73 M | $4.07 M |
| 2024 Q4 | 17 | 4.16 M | $7.53 M |
| 2024 Q3 | 17 | 4.55 M | $7.14 M |
| 2024 Q2 | 18 | 2.68 M | $2.45 M |
| 2024 Q1 | 18 | 2.67 M | $2.08 M |
| 2023 Q4 | 18 | 2.88 M | $1.47 M |
| 2023 Q3 | 12 | 2.53 M | $2.26 M |
| 2023 Q2 | 12 | 2.53 M | $3.33 M |
| 2023 Q1 | 14 | 2.89 M | $4.56 M |
| 2022 Q4 | 15 | 3.31 M | $10.6 M |
| 2022 Q3 | 16 | 3.25 M | $8.09 M |
| 2022 Q2 | 14 | 3.29 M | $12.2 M |
| 2022 Q1 | 16 | 3.31 M | $15.9 M |
| 2021 Q4 | 15 | 3.29 M | $22.7 M |
| 2021 Q3 | 16 | 3.24 M | $35.9 M |
| 2021 Q2 | 14 | 3.13 M | $59.5 M |
| 2021 Q1 | 11 | 2.88 M | $82.6 M |